ATyr Pharma

American biotherapeutics company

ATyr Pharma is a biotherapeutics company focused on the discovery and development of innovative medicines based on novel biological pathways. The company is headquartered in San Diego, California, and is engaged in the research and development of therapies for patients with rare diseases and conditions characterized by severe immune dysregulation.

History

ATyr Pharma was founded in 2005 with the aim of exploring the therapeutic potential of a newly discovered class of proteins known as tRNA synthetases. These proteins are traditionally known for their role in protein synthesis, but ATyr Pharma has been investigating their potential as signaling molecules in various biological processes.

Research and Development

The company's research focuses on the development of therapies that modulate the immune system. ATyr Pharma's lead therapeutic candidate is ATYR1923, a fusion protein designed to selectively modulate the immune response in inflammatory diseases. The company is exploring the use of ATYR1923 in conditions such as pulmonary sarcoidosis, a rare inflammatory disease affecting the lungs.

tRNA Synthetase Biology

ATyr Pharma's research is based on the novel understanding of tRNA synthetases beyond their canonical role in protein synthesis. These enzymes have been found to have additional functions in cell signaling and immune modulation. The company is leveraging this knowledge to develop new therapeutic approaches for diseases with unmet medical needs.

Clinical Trials

ATyr Pharma is conducting clinical trials to evaluate the safety and efficacy of its lead candidate, ATYR1923. The company has completed Phase 1 clinical trials and is currently engaged in Phase 2 trials for the treatment of pulmonary sarcoidosis. These trials are designed to assess the drug's ability to reduce inflammation and improve lung function in affected patients.

Collaborations and Partnerships

ATyr Pharma has established collaborations with various academic and research institutions to advance its scientific understanding and therapeutic development. These partnerships are crucial for the company's efforts to translate its discoveries into clinical applications.

Corporate Structure

The company is led by a team of experienced executives and scientists with expertise in biotechnology and drug development. ATyr Pharma is publicly traded on the NASDAQ stock exchange under the ticker symbol "LIFE."

Related pages

• Biotechnology
• Drug development
• Immune system
• Rare diseases

Gallery

• 
  Logo of ATyr Pharma